News Conference News HFSA 2025 Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM Yael L. Maxwell October 01, 2025
News Daily News ASNC Fighting Back Against Proposed Reimbursement Cuts for Amyloid Imaging Yael L. Maxwell September 11, 2025
News Conference News ESC Heart Failure 2025 HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM Todd Neale May 19, 2025
News Daily News Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM Caitlin E. Cox March 21, 2025
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for February 2025 Shelley Wood February 28, 2025
News Daily News Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time Michael O'Riordan February 13, 2025
News Daily News Acoramidis Approved in Europe for ATTR Cardiomyopathy Michael O'Riordan February 12, 2025
Presentation THT 2025 Tafamidis Impact on Incidence of Pacemaker and ICD Placement in ATTR-CM Patients Presenter: Justin Pawloski February 12, 2025
Presentation THT Abstracts 2025 Tafamidis Impact on Incidence of Pacemaker and ICD Placement in ATTR-CM Patients Presenter: Justin Pawloski February 11, 2025
Presentation THT Abstracts 2025 Determining Equity and Timeliness of ATTR-CM Diagnosis Presenter: Anubodh Varshney February 11, 2025
Presentation THT 2025 Determining Equity and Timeliness of ATTR-CM Diagnosis Presenter: Anubodh Varshney February 11, 2025
News Daily News Before a Cardiomyopathy Diagnosis, TTR Destabilization Portends Higher Mortality Yael L. Maxwell December 12, 2024
News Daily News FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy L.A. McKeown November 25, 2024
News Conference News AHA 2024 Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression Yael L. Maxwell November 20, 2024
News Conference News HFSA 2024 Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM L.A. McKeown October 04, 2024
News Conference News ESC 2024 HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM L.A. McKeown August 30, 2024
News Daily News Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B Michael O'Riordan June 24, 2024
Presentation ACC 2024 Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy Presenter: Yousuf Razvi April 06, 2024